{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:42:06Z","timestamp":1785300126848,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,13]]},"DOI":"10.7759\/cureus.64474","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T16:39:50Z","timestamp":1720888790000},"source":"Crossref","is-referenced-by-count":3,"title":["Effective Management of Life-Threatening Generalized Pustular Psoriasis Flare With Spesolimab"],"prefix":"10.7759","author":[{"given":"Efterpi","family":"Zafiriou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Karampinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Giannoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agoritsa","family":"Gravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Gampeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Zachou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston A","year":"2017","unstructured":"Johnston A, Xing X, Wolterink L, et al.. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017, 140:109-20. 10.1016\/j.jaci.2016.08.056","journal-title":"J Allergy Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12020178","article-title":"Plaque psoriasis exacerbation and COVID-19 vaccination: assessing the characteristics of the flare and the exposome parameters","volume":"12","author":"Karampinis E","year":"2024","unstructured":"Karampinis E, Papadopoulou MM, Chaidaki K, et al.. Plaque psoriasis exacerbation and COVID-19 vaccination: assessing the characteristics of the flare and the exposome parameters. Vaccines (Basel). 2024, 12:178. 10.3390\/vaccines12020178","journal-title":"Vaccines (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00881-0","article-title":"Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment","volume":"13","author":"Rivera-D\u00edaz R","year":"2023","unstructured":"Rivera-D\u00edaz R, Daud\u00e9n E, Carrascosa JM, Cueva P, Puig L. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther (Heidelb). 2023, 13:673-88. 10.1007\/s13555-022-00881-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.0915","article-title":"International consensus definition and diagnostic criteria for generalized pustular psoriasis from the International Psoriasis Council. [PREPRINT]","author":"Choon SE","year":"2024","unstructured":"Choon SE, van de Kerkhof P, Gudjonsson JE, et al.. International consensus definition and diagnostic criteria for generalized pustular psoriasis from the International Psoriasis Council. [PREPRINT]. JAMA Dermatol. 2024, 10.1001\/jamadermatol.2024.0915","journal-title":"JAMA Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418773358","article-title":"Systemic monotherapy treatments for generalized pustular psoriasis: a systematic review","volume":"22","author":"Zhou LL","year":"2018","unstructured":"Zhou LL, Georgakopoulos JR, Ighani A, Yeung J. Systemic monotherapy treatments for generalized pustular psoriasis: a systematic review. J Cutan Med Surg. 2018, 22:591-601. 10.1177\/1203475418773358","journal-title":"J Cutan Med Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2195165","article-title":"Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis","volume":"19","author":"Burden AD","year":"2023","unstructured":"Burden AD. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis. Expert Rev Clin Immunol. 2023, 19:473-81. 10.1080\/1744666X.2023.2195165","journal-title":"Expert Rev Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14294","article-title":"Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study","volume":"45","author":"Sano S","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018, 45:529-39. 10.1111\/1346-8138.14294","journal-title":"J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11081298","article-title":"Pustular eruption following COVID-19 vaccination: a narrative case-based review","volume":"11","author":"Karampinis E","year":"2023","unstructured":"Karampinis E, Gravani A, Gidarokosta P, Bogdanos DP, Roussaki-Schulze AV, Zafiriou E. Pustular eruption following COVID-19 vaccination: a narrative case-based review. Vaccines (Basel). 2023, 11:1298. 10.3390\/vaccines11081298","journal-title":"Vaccines (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial","volume":"402","author":"Morita A","year":"2023","unstructured":"Morita A, Strober B, Burden AD, et al.. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023, 402:1541-51. 10.1016\/S0140-6736(23)01378-8","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez H","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, et al.. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021, 385:2431-40. 10.1056\/NEJMoa2111563","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60331","article-title":"Spesolimab in the management of generalized pustular psoriasis with concurrent bullous pemphigoid and psoriasis","volume":"16","author":"Teshima R","year":"2024","unstructured":"Teshima R, Saito-Sasaki N, Hitaka T, Sawada Y. Spesolimab in the management of generalized pustular psoriasis with concurrent bullous pemphigoid and psoriasis. Cureus. 2024, 16:e60331. 10.7759\/cureus.60331","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.01.022","article-title":"Spesolimab use in treatment of pyoderma gangrenosum","volume":"34","author":"Gu\u00e9nin SH","year":"2023","unstructured":"Gu\u00e9nin SH, Khattri S, Lebwohl MG. Spesolimab use in treatment of pyoderma gangrenosum. JAAD Case Rep. 2023, 34:18-22. 10.1016\/j.jdcr.2023.01.022","journal-title":"JAAD Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/271039-effective-management-of-life-threatening-generalized-pustular-psoriasis-flare-with-spesolimab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T16:39:54Z","timestamp":1720888794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/271039-effective-management-of-life-threatening-generalized-pustular-psoriasis-flare-with-spesolimab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.64474","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,13]]}}}